Saint Paul, MN (PRWEB) October 28, 2010
MD Bioproducts, a division of MD Biosciences, Inc. announces the launch of a Recombinant Human ST2 protein expressed from E. coli. MD Bioproducts offers a full line of ST2 products for use in a variety of research applications:
Monoclonal Antibody to mouse T1/ST2 (clone DJ8)
Monoclonal Antibody to human ST2L (clone B4E6)
Recombinant Human ST2 Protein
Mouse T1/ST2 ELISA
The ST2 gene is a member of the IL-1 receptor family, encoding a transmembrane protein with a structure similar to IL-1R1. A soluble form of the protein (ST2) is produced from the same gene by alternative splicing and is reported to be expressed in several cell types including fibroblasts and mast cells. Soluble ST2 has been reported to act as a negative regulator of Th2 cytokine production and elavated levels have been reported in several disease states and conditions including asthma, sepsis, and myocardial infarction.
About MD Bioproducts
MD Bioproducts is a division of the privately-owned company MD Biosciences, Inc. offering products for use in the inflammations, neurology, endocrinology, and metabolic disorders research fields. Since beginning operations in the U.S., based out of St. Paul, Minnesota, MD Biosciences has experienced significant development and grown to a company of 60 employees.
About MD Biosciences
MD Biosciences provides pre-clinical contract research services for companies engaged in inflammations and neurology research. The company is headquartered in Switzerland under Morwell Diagnostics and has specialized laboratories located in Minnesota, Glasgow, and Israel. A panel of scientific experts provides companies' in-depth expertise and technologies to tackle problems and provide flexible drug discovery solutions, enabling smarter results faster.
The information in this press release should be considered accurate only as of the date of the release. MD Biosciences has no intention of updating and specifically disclaims any duty to update the information in these press releases.
# # #